In a post-hoc analysis of circulating tumor DNA (ctDNA) features from patients with metastatic prostate cancer treated with [177Lu]Lu–PSMA-617 or cabazitaxel in the randomized phase 2 TheraP trial, low ctDNA levels at baseline were predictive of clinical benefit from [177Lu]Lu–PSMA-617, and PTEN or ATM alterations were identified as potential biomarkers of response.
- Edmond M. Kwan
- Sarah W. S. Ng
- Alison Y. Zhang